Slide 1: ESG investor roadshow
ESG investor roadshow June 26, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain statements and other information that constitute forward-looking statements under applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that
Slide 3: ESG investor roadshow agenda
ESG investor roadshow agenda 01 Our sustainability strategy Audrey Duval and Sandrine Bouttier-Stref 02 Access to healthcare Christelle Saghbini and Jon Fairest 03 Environmental impact Annabelle Harreguy and Tarja Stenvall 04 Q&A 05 Resilience of healthcare systems Sandrine Bouttier-Stref and Marta
Slide 4: Speakers
Speakers Access to Environmental Resilience of healthcare impact healthcare systems Audrey Duval Christelle Saghbini Annabelle Harreguy Marta Diez Torca Executive Vice President, Corporate Affairs Head of International Pharma Head of Global Health, Safety and Global Manager Vaccines Iberia Environme
Slide 5: Execution of the social impact strategy since 2021
Execution of the social impact strategy since 2021 Affordable access Innovation for unmet Planet care In and beyond the medical needs workplace Global Health Unit IPV doses supplied Reduction of GHG Of our executives and 33m 47% 85% 43% launched to UNICEF and GAVI emissions (Scope 1&2) 46% of our se
Slide 6: Advancing our sustainability strategy, creating value through broad engagement
Advancing our sustainability strategy, creating value through broad engagement Building on achievements to Moving from flagships to Creating value for the raise ambitions One Sanofi ambition business Flagship time-bound Involve all GBUs and functions Further embed sustainability in commitments reach
Slide 7: We feel an urgency to act on the impact of the environmental crisis on health
We feel an urgency to act on the impact of the environmental crisis on health Globally, air pollution alone is responsible for Environmental challenges impact human health and healthcare systems’ resilience by… 7 million premature deaths …exacerbating certain diseases annually1. …putting healthcare
Slide 8: Environmental crisis is also a health crisis
Environmental crisis is also a health crisis A growing body of evidence supports the critical impact climate change is having on human health. 5 Key Main impacted therapeutic areas1 Environmental hazards1 Climate change, air pollution and biodiversity loss disproportionally affect patients with resp
Slide 9: Our portfolio and pipeline is already tackling diseases exacerbated by environmental change
Our portfolio and pipeline is already tackling diseases exacerbated by environmental change As a leading immunology company, we will leverage our medicines and vaccines to address these challenges 70% 78% of our portfolio of our R&D indications pipeline are targeted at diseases exacerbated by at lea
Slide 10: Sanofi's ambition: tackle the impact of environmental challenges on health and healthcare
Sanofi’s ambition: tackle the impact of environmental challenges on health and healthcare Access to Healthcare Environmental Impact Building access to care programs for Reducing environmental impact across the populations most affected by diseases value chain while adapting to climate change AIR exa
Slide 11: Sustainable and equitable access to healthcare
Sustainable and equitable access to healthcare ESG investor roadshow June 2025
Slide 12: Sustainable and equitable access to healthcare at Sanofi
Sustainable and equitable access to healthcare at Sanofi Access to healthcare for vulnerable communities within and across countries Business approaches Non-business approaches Inclusive business model Philanthropy & Classic business model humanitarian Primary objectives Full value Affordable Not-fo
Slide 13: Environmental challenges are disproportionally affecting the health of vulnerable populations
Environmental challenges are disproportionally affecting the health of vulnerable populations Global Health organizations have emphasized the need to take action to mitigate the impact of respiratory diseases on vulnerable populations The triple threat for vulnerable populations The impact on respir
Slide 14: Sanofi One Respiratory access to healthcare program
Sanofi One Respiratory access to healthcare program Enforcing the prevention and management of chronic and infectious respiratory diseases in vulnerable populations impacted by environmental change Priority areas of strategic focus 1 2 3 Drive urgency for the Close the gaps to access Strengthen heal
Slide 15: Sanofi in the US piloting equitable access programs for respiratory conditions
Sanofi in the US piloting equitable access programs for respiratory conditions Driving Equity in Flu Vaccination Community Health Center Innovation Awards Aims to improve influenza and COVID Uncover innovative solutions to respiratory and lung vaccination rates in underserved health in vulnerable co
Slide 16: Access to Diabetes Care: holistic access solutions
Access to Diabetes Care: holistic access solutions Comprehensive care programs Kids and Diabetes in School Program Mobile medical units (KiDS) • Access to diabetes care for vulnerable • Diabetes prevention and education at school • Mobile diabetes and hypertension diagnosis populations in 20+ countr
Slide 17: Global Health Unit, an integrated not-for-profit business model
Global Health Unit, an integrated not-for-profit business model… focusing on non-communicable diseases 3 40 Treatment Health system Impact strategic countries available at strengthening Investment pillars accessible prices funding • Unique go-to-market model • Co-designing and financing • Impact inv
Slide 18: Treatments available at accessible prices
Treatments available at accessible prices Making a difference for our patients in LMICs 931k 2M Patients reached with NCD treatments1 Impact, our dedicated brand 159 ~126k Regulatory Packs sold 2022 2023 2024 2025 2026 2027 2028 2029 2030 approvals (single pack Target (Accumulated) Actual (Accumulat
Slide 19: Strengthening health system
Strengthening health system Leveraging 76 partnerships to deliver “Impact” where it’s Project spotlight needed most 117 Optimizing NCD Supply Chains and tracking for Treatment Success Projects across 40 countries Tanzania Improve supply chain management for NCD medicines (38 Facilities) 254 2,335k 1
Slide 20: Impact Investment Fund: supporting the scale up of inclusive businesses
Impact Investment Fund: supporting the scale up of inclusive businesses improving care at the last mile 9.6m$ invested in 7 companies Investees highlights operating in > 15 countries Leading tech platform in South-East Asia supporting fragmented pharmacies in improving patient care and availability
Slide 21: Environmental Impact
Environmental Impact ESG investor roadshow June 2025
Slide 22: How we minimize our environmental impact
How we minimize our environmental impact With purpose and determination, we are driving a meaningful change that embeds environmental sustainability in our day-to-day operations and across our value chain. Innovating Fighting Limiting our impact with purpose climate change on nature Environmental su
Slide 23: Reducing our GHG emissions towards net zero by 2045
Fighting Climate Change Reducing our GHG emissions towards net zero by 2045 SBTi reduction targets: SBTi reduction targets1: -55% for scopes 1 & 2 by 2030 -30% for scope 3 by 2030 TOWARD NET ZERO: -90% reduction of greenhouse gas emissions across our value chain by 2045 compared to 2019 -47% -10% in
Slide 24: Offsetting our residual emissions from 2030 through carbon offsetting program
Fighting Climate Change Offsetting our residual emissions from 2030 through our community-focused carbon offsetting program Main guiding criteria for offsetting projects1: Baseline 2019 Carbon Neutrality Trajectory Net Zero 2045 5 MtCO2e 3.3 MtCO2e 500 KtCO2e All scopes Residual emissions Residual e
Slide 25: Fostering sustainable resource use and circularity
Limiting our Impact on nature Fostering sustainable resource use and circularity Optimize and turn Think of water Preserve Pharmaceuticals waste into as a valuable local biodiversity in the resources resource environment 2024 results 2024 results 2024 results 2024 results 89% -22% 70% 85% Reused, re
Slide 26: Adapting our business to the complex climate and nature-related challenges we face
Adaptation Adapting our business to the complex climate and nature-related challenges we face Leveraging prospective modelling and regular financial impacts assessment: • Mitigate our dependencies to increasingly scrace nature-based raw material and water ressources • Solve climate-related disruptio
Slide 27: Assessing our impact and dependencies on biodiversity
Adaptation Assessing our impact and dependencies on biodiversity Nature resilience analysis ongoing using the LEAP approach in line with TNFD recommendations Ongoing mitigation actions • Switch to sourcing certified cellulose/carton/paper Commodities risks’ Locate • Started substitution of horseshoe
Slide 28: Environmental sustainability by design through Eco-design
Innovating with purpose Environmental sustainability by design for our medicines and vaccines through Eco-design Our objectives Raw materials Manufacturing Adopt an Eco-design approach • From 2025 for 100% of our new products • By 2030 for our 20 top-selling products Assessing and Product reducing o
Slide 29: Championing sustainability through Eco-Design and Circularity with our insulins
Innovating with purpose 450 With our insulins, we are serious about championing sustainability through Eco-Design and Circularity Million insulin pens manufactured in 2024 2025 2026 2027 2028 2029 2030 AllStar® (Lantus) Reusable Pens TouStar ® Approx. (Toujeo) equivalent to 60 disposable pens1 EcoSt
Slide 30: Creating business value through continuous improvement
Innovating with purpose Creating business value through continuous improvement Dupixent -53% CO2 impact vs 2019 ALTUVIIIO -53% CO2 impact vs Eloctate 2nd vs. 1st generation API, energy, device and solvents Results for 1 year of treatment Climate change (kgCO2eq) Ecotox freshwater (CTUe) Climate chan
Slide 31: Q&A session part 1
Q&A session part 1 Access to Environmental Resilience of healthcare impact healthcare systems Audrey Duval Christelle Saghbini Annabelle Harreguy Marta Diez Torca Executive Vice President, Corporate Affairs Head of International Pharma Head of Global Health, Safety and Global Manager Vaccines Iberia
Slide 32: Resilience of Healthcare systems
Resilience of Healthcare systems ESG investor roadshow June 2025
Slide 33: Healthcare sector emissions
What’s at stake? Healthcare sector emissions 5% 50% R&D Products & supply chain The healthcare sector accounts for 5% of global carbon emissions 45% Patient Care Pathway (PCP) 33 33 ESG Investor Roadshow
Slide 34: Driving decarbonization in healthcare: SMI Patient Care Pathway Working Group
Driving decarbonization in healthcare: Sanofi is leading the SMI Patient Care Pathway Decarbonization Working 1 Healthcare policies Encouraging the +90 countries that are part of the Group WHO ATACH Alliance to prioritize healthcare policies aligned with 2030 and 2045 goals. 2030 2045 Sustainable “l
Slide 35: Patient care pathway action levers
Patient care pathway action levers Seven levers of decarbonization Improving prevention and care Delivering care differently Decarbonizing Diagnosing Preventing disease Optimizing disease Improving Delivering care Using lower fleets early onset management intervention remotely emissions Reducing hea
Slide 36: Integrating environmental insights into our R&D tools
Integrating environmental insights into our R&D tools With a comprehensive understanding of the implications of a changing environment on human health we are better equipped to consider environment factors as a part of our strategy. Better understanding Comprehensive dataset on Integrated into our e
Slide 37: Beyfortus: simplifying and expanding RSV protection to all infants
Beyfortus: simplifying and expanding RSV protection to all infants palivizumab • Long-acting monoclonal antibody approved by the EMA in 2022 to prevent serious lower respiratory RSV is a leading tract disease caused by RSV in infants during their ~1.5% eligible population cause of hospitalization 1s
Slide 38: Assessing Beyfortus Net GHG impact along the Patient Care Pathway
Assessing Beyfortus Net GHG impact along the Patient Care Pathway Patient care pathway of Beyfortus vs SoC ~318k additional injections Drug uptake patient 1 Broader population coverage journey ~152k additional visits vs standard of care Net impact Avoided 118k PC visits Avoided disease burden Less r
Slide 39: Beyfortus reduces RSV-related emissions by 47% in Spain
Beyfortus allows to reduce the RSV-related emissions by 47% when applied to the whole infant population < 1y.o. in Spain Net GHG impact for Beyfortus in Spain, in ktons CO2eq / year The implementation of Beyfortus in ~+2.9 ktons Spain results in CO2eq / year ~-7.8 ktons -47% CO2eq / year -4.9 ktons
Slide 40: Other examples of Sanofi PCP action levers for decarbonization
Other examples of Sanofi PCP action levers for decarbonization FR Efluelda 5 to 33Kt Up to eq. to The high-dose flu vaccine for the elderly could reduce CO2 CO 2 avoided -9% = 51,900 in emissions / in emissions emissions up to 9% compared to the standard dose1. year in France vs Soc return flights b
Slide 41: Taking the lead in inclusion
Taking the lead in inclusion ESG investor roadshow June 2025
Slide 42: We are continually pushing forward
We are continually pushing forward From competence to confidence 2025-2030 2021-2024 Belong. Beyond Diversity edge Boundaries Unleashed an unrelenting Drive innovation further drive to improve culture and and serve patients better by competence, to reflect the embedding inclusion and patients we ser
Slide 43: Belong. Beyond Boundaries
Belong. Beyond Boundaries By 2030 we will have inclusion embedded into every decision and process, fostering belonging that drives innovation, trust, and better outcomes for patients. Patients People Places Build fairness for all in healthcare Ensure widespread ownership Create a Sanofi standard of
Slide 44: Key take aways
Key take aways Sanofi’s refreshed sustainability strategy, AIR, tackles the impact of environmental challenges on health and healthcare • Access to healthcare We tackle access to care for conditions exacerbated by environmental change, including respiratory conditions and diabetes and via our Global
Slide 45: Q&A session Part 2
Q&A session Part 2 Access to Environmental Resilience of healthcare impact healthcare systems Audrey Duval Christelle Saghbini Annabelle Harreguy Marta Diez Torca Executive Vice President, Corporate Affairs Head of International Pharma Head of Global Health, Safety and Global Manager Vaccines Iberia
Slide 46: Abbreviations
Abbreviations AIR Access, Impact, Resilience (Sanofi's sustainability strategy) IPV Inactivated Polio Vaccine ARR Afforestation, Reforestation and Revegetation KiDS Kids and Diabetes in School Program ATACH Alliance for Transformative Action on Climate and Health KtCO2e Kilotonne of CO2 equivalent B
Slide 47: sanofi
sanofi